News Feed Opinion Career Insight Dialogues Blog Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Juan P. Alderuccio: BTK inhibitors and degraders in Lymphoma and Chronic Lymphocytic Leukemia
Juan P. Alderuccio/X
Nov 4, 2024, 13:37

Juan P. Alderuccio: BTK inhibitors and degraders in Lymphoma and Chronic Lymphocytic Leukemia

Juan P. Alderuccio, Lymphoma Physician at Sylvester Comprehensive Cancer Center, shared on X about recent paper by him as co-author, titled “Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia” published on Nature Reviews Clinical Oncology.

Authors: Michele D. Stanchina, Skye Montoya, Alexey V. Danilov, Jorge J. Castillo, Alvaro J. Alencar, Julio C. Chavez, Chan Y. Cheah, Carlos Chiattone, Yucai Wang, Meghan Thompson, Paolo Ghia, Justin Taylor, Juan Pablo Alderuccio

Juan P. Alderuccio: BTK inhibitors and degraders in Lymphoma and Chronic Lymphocytic Leukemia

“Happy to share our paper on BTK inhibitors and degraders in lymsm and CLL with the participation of outstanding colleagues.”

Alexey V. Danilov Alvaro J. Alencar cancer Carlos Chiattone Chan Y. Cheah Jorge J. Castillo Juan P. Alderuccio Julio C. Chavez Justin Taylor Meghan Thompson Michele D. Stanchina Nature Reviews OncoDaily Oncology Paolo Ghia Skye Montoya Yucai Wang
Special Coverage
Insight
Nov 4, 2024, 14:04
Raffaele Colombo: Insights from October: Advances in ADC research and cancer therapeutics
Insight
Nov 4, 2024, 13:50
Esra Bilir: Driving meaningful change in gynecologic oncology
Blog
Nov 4, 2024, 13:41
AF1q as a promising new biomarker for neuroblastoma
Blog
Nov 4, 2024, 13:40
Fumiko Ladd Chino: An amazing Boot Walk to End Cancer
Blog
Nov 4, 2024, 13:37
Juan P. Alderuccio: BTK inhibitors and degraders in Lymphoma and Chronic Lymphocytic Leukemia
Insight
Nov 4, 2024, 13:32
Paolo Tarantino: The SERENA-2 phase 2 trial of camizestrant vs fulvestrant is out
Insight
Nov 4, 2024, 13:28
Strategies to prevent and manage antibody-drug conjugate-associated nausea and vomiting
Blog
Nov 4, 2024, 12:46
Interventions and implementation efforts to address disparities in genetic services research
Blog
Nov 4, 2024, 12:41
The 2025 CancerX Moonshot Accelerator program is still open for applications
Blog
Nov 4, 2024, 12:36
Erman Akkus: Liver transplantation for Transplant Oncology indications
Blog
Nov 4, 2024, 12:31
Abhishek Shankar: Honored to Chair for the IGCS-IGCAN Cancer Survivors Caregivers Summit
Blog
Nov 4, 2024, 12:30
Heather McGee: Genetic Variation and Regulation of MICA in Early-Onset Colorectal Cancer